Osteoporosis historical perspective: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Usama Talib (talk | contribs) |
||
| Line 47: | Line 47: | ||
|} | |} | ||
* 4000 years old Egyptian mummies showed the sign of [[osteoporosis]] | * 4000 years old Egyptian mummies showed the first sign of [[osteoporosis]] known as "Dowager's hump". Bone with holes, was seen for the first time. | ||
* John Hunter found that the [[bones]] in the [[human body]] turn over continuously | * John Hunter found that the [[bones]] in the [[human body]] turn over continuously. When some old or dysfunctioned [[bone]] tissue is eliminated, it is latter substituted by new tissue. This process is known as remodeling. | ||
* In 1830's, Jean Lobstein, a French [[pathologist]], found that there holes in every [[bones|bone]]; but [[bones]] of people of specific age and suffering from | * In 1830's, Jean Lobstein, a French [[pathologist]], found that there are holes in every [[bones|bone]]; but [[bones]] of people of specific age and suffering from certain [[diseases]] may have bigger holes than regular ones. Jean Lobstein eventually named this kind of [[bones|bone]] <nowiki/>as [[porous|''porous'']]'','' and the [[disease]] got its name; ''[[osteoporosis]]''.<ref name="urlHistory of Osteoporosis">{{cite web |url=http://reliawire.com/history-osteoporosis/ |title=History of Osteoporosis |format= |work= |accessdate=}}</ref> | ||
* In 1830's, the | * In 1830's, the association between age-related reductions in [[bone]] [[density]] and [[Bone fracture|fracture]] risk was determined by Astley Cooper. The term "[[osteoporosis]]" and the recognition of its [[pathological]] appearance is generally attributed to the French [[pathologist]], Lobstein.<ref>Lobstein JGCFM. ''Lehrbuch der pathologischen Anatomie.'' Stuttgart: Bd II, 1835.</ref> | ||
* In 1940's, | * In 1940's, an American [[endocrinologist]], Fuller Albright from [[Massachusetts General Hospital]], established an association between [[osteoporosis]] and [[postmenopausal]] state. Fuller Albright started to treat [[menopausal]] women with [[estrogen]] in order to prevent further [[bone]] loss.<ref>{{cite journal | author=Albright F, Bloomberg E, Smith PH|year=1940 |month= |title= Postmenopausal osteoporosis |journal=Trans. Assoc. Am. Physicians. |volume=55 |pages=298-305}}</ref> | ||
* In 1960's, researchers developed more sensitive methods to detect early [[bone loss]], such as bone densitometers. | * In 1960's, researchers developed more sensitive methods to detect early [[bone loss]], such as bone densitometers. | ||
* In 1960's, [[bisphosphonates]] which inhibit [[bone]] resorption, | * In 1960's, [[bisphosphonates]] which inhibit [[bone]] resorption, revolutionized the treatment of [[osteoporosis]] after they were discovered by Herbert Fleisch.<ref>{{cite journal|author=Patlak M |title=Bone builders: the discoveries behind preventing and treating osteoporosis |journal=FASEB J. |volume=15|issue=10 |pages=1677E–E |year=2001 |pmid=11481214 |doi=}}</ref> | ||
* In 1984, the [[National Institute of Health|National Institute of Health (NIH)]] publicized [[osteoporosis]] as a significant threat to [[health]] and the possibility that [[bone loss]] | * In 1984, the [[National Institute of Health|National Institute of Health (NIH)]] publicized [[osteoporosis]] as a significant threat to [[health]] and the possibility that [[bone loss]] may be reduced by [[estrogen]] therapy, [[calcium]] supplementation, good [[nutrition]], and [[Physical exercise|exercise]].<ref name="urlThe National Institutes of Health (NIH) Consensus Development Program: Osteoporosis">{{cite web |url=https://consensus.nih.gov/1984/1984Osteoporosis043html.htm |title=The National Institutes of Health (NIH) Consensus Development Program: Osteoporosis |format= |work= |accessdate=}}</ref> | ||
* In 1980's and 1990's researchers discovered the specific [[cytokines]] which influence the activity of [[osteoclasts]], the components that lead to [[bone]] breakdown.<ref name="pmid26491648">{{cite journal| author=Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R| title=The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. | journal=Anal Cell Pathol (Amst) | year= 2015 | volume= 2015 | issue= | pages= 434389 | pmid=26491648 | doi=10.1155/2015/434389 | pmc=4605147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26491648 }} </ref> | * In 1980's and 1990's researchers discovered the specific [[cytokines]] which influence the activity of [[osteoclasts]], the components that lead to [[bone]] breakdown.<ref name="pmid26491648">{{cite journal| author=Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R| title=The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis. | journal=Anal Cell Pathol (Amst) | year= 2015 | volume= 2015 | issue= | pages= 434389 | pmid=26491648 | doi=10.1155/2015/434389 | pmc=4605147 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26491648 }} </ref> | ||
* In 1994, [[World Health Organization|World Health Organization (WHO)]] first used T-score for classification of various amounts of [[Bone mineral density|bone mineral density (BMD)]]. The | * In 1994, [[World Health Organization|World Health Organization (WHO)]] first used T-score for classification of various amounts of [[Bone mineral density|bone mineral density (BMD)]]. The sample population consisted of young, healthy individuals, matched for sex and [[race]].<ref name="pmid7941614">{{cite journal |vauthors= |title=Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group |journal=World Health Organ Tech Rep Ser |volume=843 |issue= |pages=1–129 |year=1994 |pmid=7941614 |doi= |url=}}</ref> | ||
* In 1998, [[Selective estrogen receptor modulator|selective estrogen receptor modulators (SERMs)]], such as [[raloxifene]], | * In 1998, [[Selective estrogen receptor modulator|selective estrogen receptor modulators (SERMs)]], such as [[raloxifene]], were introduced in the market. They have also been found to treat [[breast tumors]] and stimulate the [[growth]] of [[uterine]] cells.<ref name="raloxifen">{{cite book | last = Macor| first = John| title = Annual reports in medicinal chemistry | publisher = Elsevier/Academic Press | location = London, UK | year = 2008 | isbn = 9780123743442 }}</ref> | ||
==References== | ==References== | ||
Revision as of 21:03, 3 October 2017
|
Osteoporosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Medical Therapy |
|
Case Studies |
|
Osteoporosis historical perspective On the Web |
|
American Roentgen Ray Society Images of Osteoporosis historical perspective |
|
Risk calculators and risk factors for Osteoporosis historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Eiman Ghaffarpasand, M.D. [2]
Overview
Osteoporosis was first discovered by John Hunter, a British surgeon, in 1800's. John Hunter found that the bones in the human body turn over continuously, when some old or dysfunctioned bone tissue is eliminated, to be latter substituted by new tissue. This process is also known as remodeling. Jean Lobstein, a French pathologist during 1830's, found that there are small holes in every bone but bones in people with specific age and diseases, have holes of larger than normal size. He named this kind of bones as porous, and the disease was named as osteoporosis.
Historical perspective
The historical perspective of osteoporosis has been given below:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- 4000 years old Egyptian mummies showed the first sign of osteoporosis known as "Dowager's hump". Bone with holes, was seen for the first time.
- John Hunter found that the bones in the human body turn over continuously. When some old or dysfunctioned bone tissue is eliminated, it is latter substituted by new tissue. This process is known as remodeling.
- In 1830's, Jean Lobstein, a French pathologist, found that there are holes in every bone; but bones of people of specific age and suffering from certain diseases may have bigger holes than regular ones. Jean Lobstein eventually named this kind of bone as porous, and the disease got its name; osteoporosis.[1]
- In 1830's, the association between age-related reductions in bone density and fracture risk was determined by Astley Cooper. The term "osteoporosis" and the recognition of its pathological appearance is generally attributed to the French pathologist, Lobstein.[2]
- In 1940's, an American endocrinologist, Fuller Albright from Massachusetts General Hospital, established an association between osteoporosis and postmenopausal state. Fuller Albright started to treat menopausal women with estrogen in order to prevent further bone loss.[3]
- In 1960's, researchers developed more sensitive methods to detect early bone loss, such as bone densitometers.
- In 1960's, bisphosphonates which inhibit bone resorption, revolutionized the treatment of osteoporosis after they were discovered by Herbert Fleisch.[4]
- In 1984, the National Institute of Health (NIH) publicized osteoporosis as a significant threat to health and the possibility that bone loss may be reduced by estrogen therapy, calcium supplementation, good nutrition, and exercise.[5]
- In 1980's and 1990's researchers discovered the specific cytokines which influence the activity of osteoclasts, the components that lead to bone breakdown.[6]
- In 1994, World Health Organization (WHO) first used T-score for classification of various amounts of bone mineral density (BMD). The sample population consisted of young, healthy individuals, matched for sex and race.[7]
- In 1998, selective estrogen receptor modulators (SERMs), such as raloxifene, were introduced in the market. They have also been found to treat breast tumors and stimulate the growth of uterine cells.[8]
References
- ↑ "History of Osteoporosis".
- ↑ Lobstein JGCFM. Lehrbuch der pathologischen Anatomie. Stuttgart: Bd II, 1835.
- ↑ Albright F, Bloomberg E, Smith PH (1940). "Postmenopausal osteoporosis". Trans. Assoc. Am. Physicians. 55: 298–305.
- ↑ Patlak M (2001). "Bone builders: the discoveries behind preventing and treating osteoporosis". FASEB J. 15 (10): 1677E–E. PMID 11481214.
- ↑ "The National Institutes of Health (NIH) Consensus Development Program: Osteoporosis".
- ↑ Pagliari D, Ciro Tamburrelli F, Zirio G, Newton EE, Cianci R (2015). "The role of "bone immunological niche" for a new pathogenetic paradigm of osteoporosis". Anal Cell Pathol (Amst). 2015: 434389. doi:10.1155/2015/434389. PMC 4605147. PMID 26491648.
- ↑ "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group". World Health Organ Tech Rep Ser. 843: 1–129. 1994. PMID 7941614.
- ↑ Macor, John (2008). Annual reports in medicinal chemistry. London, UK: Elsevier/Academic Press. ISBN 9780123743442.